Hester Biosciences Limited

524669

INE782E01017

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:50 15/05/2026 pm IST			5-day change	1st Jan Change
1,834.05 ^INR	+5.67%		+11.18%	+15.21%

15/05	Hester Biosciences Limited, Q4 2026 Earnings Call, May 15, 2026
15/05	Hester Biosciences' Consolidated Profit Soars in Fiscal Q4; Shares Jump 10%	MT

Hester Biosciences approves divestment of 43.81% equity in Texas Lifesciences

Published on 03/11/2026 at 12:28 pm IST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Hester Biosciences Limited

15/05	Hester Biosciences Limited, Q4 2026 Earnings Call, May 15, 2026
15/05	Hester Biosciences' Consolidated Profit Soars in Fiscal Q4; Shares Jump 10%	MT
15/05	Hester Biosciences March-quarter consol net profit 159.8 million rupees	RE
15/05	Hester Biosciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2026	CI
11/03	Hester Biosciences Gets Board Nod to Divest 43.8% Stake in Subsidiary; Shares Up 3%	MT
11/03	Hester Biosciences approves divestment of 43.81% equity in Texas Lifesciences	RE
11/03	Ticop Life Private Limited entered into an agreement to acquire an additional 43.81% stake in Texas Laboratories from Hester Biosciences Limited for INR 92 million.	CI
30/01	Hester Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
30/01	Hester Biosciences Limited, Q3 2026 Earnings Call, Jan 30, 2026
30/01	Hester Biosciences re-appoints Rajiv Gandhi as CEO & MD	RE
24/01	Hester Biosciences Limited Receives the Manufacturing License from the Food & Drugs Control Administration	CI
20/11	Hester Biosciences says Ashish Desai appointed as chief financial officer	RE
20/11	Hester Biosciences Appoints CFO	MT
20/11	Hester Biosciences Limited Appoints Ashish Desai as Key Managerial Personnel, with Effect from 20 November 2025	CI
20/11	Hester Biosciences Limited Appoints Ashish Desai as Chief Financial Officer, with Effect from 20 November 2025	CI

Chart Hester Biosciences Limited

Duration

Period

524669: Dynamic Chart

Hester Biosciences Limited is an India-based animal healthcare company. The Company is principally engaged in manufacturing poultry vaccines, large animal vaccines, and trading poultry, large animal, and petcare health products. Its segments include Poultry Healthcare, Animal Healthcare, and Others. The Poultry Healthcare vaccines include Gumboro I, Inactivated Chick ND, Inactivated Coryza, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IBD, among others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, PPR Vaccine - Sungri/96, among others. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet, Pawfresh, Synoton, Petsglow, Vitacoat, WormPeril, Hestaliv, TumOnzym and Safeline Spot. Its manufacturing facility is located at Village Meda-Adraj, Taluka Kadi, Mehsana District, Gujarat.

Employees

562

Sector

Pharmaceuticals

Calendar

Earnings release - Q4 2026

More about the company